Come up with a name for your new list and we'll add to it:
Pelican Therapeutics raised a round of funding on May 19, 2016. Investors include
Cancer Prevention and Research Institute of Texas.
Pelican Therapeutics is developing biologic agents that represent the next generation of TNF based immunotherapy. TNFRSF25 agonists provide a CD8+ T cell and Th1-type antibody adjuvant signal when use…